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Abstract
This study was performed to investigate the transduction of a
full-length superoxide dismutase (SOD) protein fused to
transactivator of transcription (Tat) into human chondrocytes,
and to determine the regulatory function of transduced Tat-SOD
in the inflammatory cytokine induced catabolic pathway. The
pTat-SOD expression vector was constructed to express the
basic domain of HIV-1 Tat as a fusion protein with Cu, Zn-SOD.
We also purified histidine-tagged SOD without an HIV-1 Tat and
Tat-GFP as control proteins. Cartilage samples were obtained
from patients with osteoarthritis (OA) and chondrocytes were
cultured in both a monolayer and an explant. For the
transduction of fusion proteins, cells/explants were treated with
a variety of concentrations of fusion proteins. The transduced
protein was detected by fluorescein labeling, western blotting
and SOD activity assay. Effects of transduced Tat-SOD on the
regulation of IL-1 induced nitric oxide (NO) production and
inducible nitric oxide synthase (iNOS) mRNA expression was
assessed by the Griess reaction and reverse transcriptase PCR,
respectively. Tat-SOD was successfully delivered into both the
monolayer and explant cultured chondrocytes, whereas the
control SOD was not. The intracellular transduction of Tat-SOD
into cultured chondrocytes was detected after 1 hours, and the
amount of transduced protein did not change significantly after
further incubation. SOD enzyme activity increased in a dose-
dependent manner. NO production and iNOS mRNA
expression, in response to IL-1 stimulation, was significantly
down-regulated by pretreatment with Tat-SOD fusion proteins.
This study shows that protein delivery employing the Tat-protein
transduction domain is feasible as a therapeutic modality to
regulate catabolic processes in cartilage. Construction of
additional Tat-fusion proteins that can regulate cartilage
metabolism favorably and application of this technology in in
vivo models of arthritis are the subjects of future studies.
Introduction
Osteoarthritis (OA) is a degenerative disease of articular car-
tilage and causes significant morbidity in humans. It is charac-
terized by loss of articular cartilage matrix, mainly collagen and
proteoglycans, leading to tissue destruction and cell death,
eventually resulting in loss of joint function. Although OA is fre-
quently regarded as a noninflammatory form of arthritis, con-
siderable data implicate proinflammatory cytokines derived
from both the synovium and the chondrocytes in cartilage
destruction. IL-1 and its downstream mediators, such as
inducible nitric oxide synthase (iNOS), cyclooxygenase 2
(COX-2) and phospholipase A2, are postulated as the impor-
tant factors in the inflammatory cascade of OA [1]. Also, IL-1
has been shown to induce chondrocytes to produce the reac-
tive oxygen species (ROS), which act as second messengers
in the intracellular signaling pathways involved in activation of
proinflammatory responses and mediate degradation of aggre-
gan and collagen [2]. Overproduction of the ROS also causes
apoptosis and necrosis, resulting in cellular damage [3]. Cell
defense against the ROS utilizes antioxidant enzymes such as
superoxide dismutase (SOD), catalase, and glutathione perox-
idase [4]. SOD catalyzes the breakdown of superoxide to gen-
erate hydrogen peroxide. Catalase and glutathione
peroxidases are two cellular defenses that serve to remove
hydrogen peroxide by decomposing it into water and oxygen
and to reduce generation of hydroxyl radicals [5]. Therefore,
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these enzymes are vital for maintaining a balanced cellular
redox state and therapeutic manipulation of them is thought to
have a role in combating the toxic effects of oxygen free radical
induced damage.
A variety of therapeutic strategies for OA have been devel-
oped to antagonize the activity of proinflammatory cytokines.
These strategies include gene delivery techniques, such as ex
vivo gene transfer of glucuronosyltransferase-I [6], retrovirus
expression of IL-1 receptor antagonists [7], and adenovirus-
mediated overexpression of transforming growth factor-β [8].
Although gene therapy has been considered a promising
method for introducing therapeutic molecules into cells, this
technique bears significant constraints, such as efficacy of
gene delivery, duration of gene expression and toxicity. Previ-
ously, it has been reported that the basic domain of the HIV-1
transactivator of transcription (Tat) protein, which is com-
posed of 11 amino acid residues, possesses the ability to
traverse biological membranes efficiently in a process termed
'protein transduction' [9,10]. The HIV-1 Tat protein transduc-
tion domain (PTD), in common with similar domains found in
VP22 from the herpes simplex virus [11] and Antennapedia
from Drosophila [12], is a region rich in positively charged
amino acids that are thought to interact with negatively
charged phospholipids in the mammalian plasma membrane.
The transduction occurs by a receptor- or transporter-inde-
pendent fashion that appears to target the lipid bilayer directly
[13]. HIV-1 Tat proteins thus have been shown to serve as car-
riers that direct uptake of various heterologous proteins into
cells in vitro and in vivo. Recently, this property has been used
in therapeutic applications. In this study, we showed that the
full-length SOD protein fused to HIV-1 Tat PTD is transduced
into human chondrocytes, both in monolayer and explant cul-
tures, and that the transduced fusion protein has a regulatory
function for the IL-1 induced catabolic pathway in
chondrocytes.
Materials and methods
Reagents
Recombinant human IL-1β was obtained from R&D systems
(Minneapolis, MN, USA). Anti-polyhistidine IgG was pur-
chased from Santa Cruz Biotechnologies (Santa Cruz, CA,
USA). Nitrate/nitrite colorimetric assay kits were purchased
from Cayman Chemical (Ann Arbor, MI, USA). Restriction
endonucleases and T4 DNA ligase were purchased from
Promega (Madison, WI, USA). Pfu polymerase was obtained
from Stratagene (La Jolla, CA, USA). TA-cloning vector was
obtained from Invitrogen (Carlsbad, CA, USA). Oligonucle-
otides were synthesized from Gibco BRL custom primers
(Carlsbad, CA, USA). Isopropyl-β-D-thiogalactoside (IPTG)
was obtained from Duchefa (Haarlem, the Netherlands). Plas-
mid pET15b and Escherichia coli strain BL21 (DE3) were
from Novagen (Madison, WI, USA). Ni2+-nitrilotriacetic acid
Sepharose superflow was purchased from Qiagen (Hilden,
Germany). A human Cu, Zn-SOD cDNA fragment was isolated
using the PCR technique from the λZap human placenta cDNA
library [14] and a monoclonal antibody against human Cu, Zn-
SOD was produced in our laboratory. All other reagents were
obtained from Sigma (St. Louis, MO, USA) unless specified
otherwise.
Expression and purification of Tat-SOD
The pTat-SOD expression vector was constructed to express
the basic domain (amino acids 49 to 57) of HIV-1 Tat as a
fusion protein with Cu, Zn-SOD, as described previously [15].
Briefly, two oligonucleotides were synthesized and annealed
to generate a double-stranded oligonucleotide encoding nine
amino acids from the basic domain of HIV-1 Tat. The
sequences were: top strand, 5'-TAGGAAGAAGCGGA-
GACAGCGACGAAGAC-3'; and bottom strand, 5'-TCGAG-
TCTTCGTCGCTGTCTCCGCTTCTTCC-3'. The double-
stranded oligonucleotide was directly ligated into the NdeI-
XhoI-digested pET15b in frame with the six histidine open-
reading frames to generate the HisTat expression plasmid,
pHisTat. Next, on the basis of the cDNA sequence of human
Cu, Zn-SOD, two oligonucleotides were synthesized. The top
strand, 5'-CTCGAGGCGACGAAGGCCGTGTGCGTG-3',
contained a XhoI restriction site, and the bottom strand, 5'-
GGATCCTTATTG-GGCGATCCCAATTAC-3', contained a
BamHI restriction site. The reaction mixture was made up in a
50 µl siliconized reaction tube and heated at 94°C for 5 min-
utes. The program for PCR consisted of 30 cycles of denatur-
ation at 94°C for 40 seconds, annealing at 54°C for 1 minute,
and elongation at 70°C for 3 minutes, and the final extension
at 72°C for 10 minutes. The PCR products were purified by
preparative agarose gel electrophoresis. The purified products
were ligated into a TA-cloning vector and then transformed
into a competent cell. The bacterial cells (E. coli BL21) trans-
formed with pTat-SOD were harvested and disrupted by son-
ication in 5 ml binding buffer (5 mM imidazole, 0.5 M NaCl, 20
mM Tris-HCl, pH 7.9) containing 6 M urea. After centrifuga-
tion, supernatant was immediately loaded onto a 2.5 ml Ni2+-
nitrilotriacetic acid Sepharose column (Qiagen, Valencia, CA,
USA). After the column was washed with 10 volumes of a
binding buffer and 6 volumes of a washing buffer (60 mM imi-
dazole, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9), the fusion pro-
tein was eluted with an elution buffer (1 M imidazole, 0.5 M
NaCl, 20 mM Tris-HCl, pH 7.9). The fusion protein containing
fractions were combined and the salts were removed using
PD10 column chromatography. To enhance the transduction
efficacy of Tat-SOD, copper ion recovery of overexpressed
Tat-SOD was conducted as described previously [16]. We
purified six histidine residue-tagged SODs without an HIV-1
Tat PTD by using a SOD expression vector (pSOD) as a con-
trol SOD protein. pTat-green fluorescent protein (GFP) was
also constructed to express the basic domain of HIV-1 Tat as
a fusion with GFP as was described previously [17] and used
as a control Tat protein.Available online http://arthritis-research.com/content/8/4/R96
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Chondrocyte culture
Cartilage samples were obtained from the femoral condyle
and tibial plateau of OA patients at the time of joint replace-
ment surgery. All cartilage samples were procured after
obtaining oral informed consent from the patients and institu-
tional approval. Chondrocytes from articular cartilage were
cultured in monolayer as described previously [18]. After
about seven days, confluent chondrocytes were split once,
plated and these first passage adherent chondrocytes were
used in subsequent experiments. For cartilage explant culture,
full-thickness cartilage slices were obtained above the
subchondral bone from a relatively lesion-free area of the fem-
oral condyle of OA patients. Each slice was cut further and a
piece of approximately 2 mm width by 5 mm length by full
thickness was cultured in a 48-well culture plate in 200 µl per
well of the same medium in which monolayer chondrocytes
were cultured. Explants were incubated in the medium for
three days before protein transduction to allow them to stabi-
lize in in vitro conditions.
Transduction of Tat-SOD into chondrocytes
For the transduction of Tat-SOD protein into the monolayer
cultured chondrocytes, cells were seeded at 5 × 105/well in
six well plates. Then, the culture medium was replaced with 1
ml of fresh serum free DMEM containing various concentra-
tions of fusion protein. For the transduction of Tat-SOD into
the cartilage explant culture, the culture medium was replaced
with 200 µl of fresh serum free DMEM containing various con-
centrations of fusion proteins. The transduction procedures
were the same for control SOD and Tat-GFP proteins.
Western blot analysis
Monolayer cultured chondrocytes were extensively washed
after protein transduction, and trypsinized. Cellular proteins
were extracted in lysis buffer containing 50 mM sodium ace-
Figure 1
Transduction of transactivator of transcription (Tat)-superoxide dismutase (SOD) fusion protein into monolayer cultured chondrocytes Transduction of transactivator of transcription (Tat)-superoxide dismutase (SOD) fusion protein into monolayer cultured chondrocytes. Chondro-
cytes were obtained from the femoral condyle and the tibial plateau from osteoarthritis (OA) patients and cultured in monolayers. First passage 
chondrocytes were used in subsequent experiments. (a) Dose-dependent and (b) time-dependent transduction of Tat-SOD into chondrocytes. 
Transduction of Tat-SOD into the cells was analyzed by western blotting with a rabbit anti-polyhistidine IgG. Tat-SOD (1 to 7 µM) and control SOD 
were added to the culture medium for 1 hour (a), or 3 µM of Tat-SOD and control SOD were added to the culture medium for 1 to 9 hours (b). (c) 
Localization of transduced Tat-SOD protein. After FITC-labeled Tat-SOD (3 µM) was transduced into chondrocytes, the cells were washed with 
PBS and immediately observed by fluorescence microscopy (×100 original magnification; inset, ×400 original magnification). Data are representa-
tive of four samples from different donors. (d) The specific activities of SOD in cultured chondrocytes treated with Tat-SOD; 1 to 7 µM of Tat-SOD 
and control SOD were added to the culture medium for 1 hours. Bars represent the mean ± standard error of the mean obtained from duplicate 
experiments from three donors. Asterisks denote p < 0.05 compared to control.Arthritis Research & Therapy    Vol 8 No 4    Kim et al.
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tate, pH 5.8, 10% v/v SDS, 1 mM EDTA, 1 mM phenylmethyl-
sulfonyl fluoride, and 1 µg/ml aprotinin at 4°C. Western
blotting was performed as described previously [18], using a
rabbit anti-polyhistidine IgG (Santa Cruz Biotechnologies;
dilution 1:500), the epitope of which is specific for the polyhis-
tidine domain of Tat-SOD and control SOD. For explant-cul-
tured chondrocytes, tissues were milled in liquid nitrogen after
protein transduction and extensive washing. Protein was
extracted in 4 M guanidine hydrochloride buffer containing 50
mM sodium acetate, pH 5.8, 1 mM phenylmethylsulfonyl fluo-
ride, and 1 µg/ml aprotinin at 4°C and dialyzed. Electrophore-
sis and western blotting procedures were the same as those
for monolayer chondrocytes.
SOD enzyme assay
Proteins extracted from the monolayer chondrocytes were
used for the analysis of dismutase activity of SOD. The inhibi-
tion of ferricytochrome c reduction by the xanthine/xanthine
oxidase reaction was monitored, according to a method
reported previously [19]. The standard assay was performed
in 3 ml of 50 mM potassium phosphate buffer at pH 7.8 con-
taining 0.1 mM EDTA in a cuvette at 25°C. The reaction mix-
ture contained 10 µM ferricytochrome c, 50 µM xanthine and
sufficient xanthine oxidase to produce a rate of reduction of
ferricytochrome c at 550 nm of 0.025 absorbance unit per
minute. Under these defined conditions, the amount of super-
oxide dismutase required to inhibit the rate of reduction of fer-
ricytochrome c by 50% is defined as 1 unit of activity.
Fluorescence analysis and immunohistochemistry
For direct detection of transduced SOD protein in monolayer
cultured chondrocytes, purified Tat-SOD and control SOD
were labeled with FITC using an EZ-Label FITC protein labe-
ling kit according to the manufacturer's instructions (Pierce,
Rockford, IL, USA). Chondrocytes were seeded on glass cov-
erslips and treated with 3 µM Tat-SOD or control SOD pro-
teins. After incubation for 1 hour at 37°C, the cells were
washed extensively with PBS. The distribution of fluorescence
in non-fixed cells was analyzed with a Carl Zeiss Axiophot flu-
orescence microscope (Oberkochen, Germany). Immunohis-
tochemical studies were carried out to identify transduced Tat-
SOD in cartilage explant cultures. The cartilage explants were
fixed with 4% paraformaldehyde after protein transduction and
extensive washing. After fixation, explants were stored in 30%
sucrose in PBS, and then cut in a cryotome. After removal of
non-specific immunoreactivity using 0.3% Triton X-100 and
Figure 2
Transduction of transactivator of transcription (Tat)-superoxide dismutase (SOD) fusion protein into explant cultured chondrocytes Transduction of transactivator of transcription (Tat)-superoxide dismutase (SOD) fusion protein into explant cultured chondrocytes. Chondrocytes 
were obtained from a relatively lesion-free area of femoral condyles in OA patients and cultured in explants. (a) Transduction of Tat-SOD into the 
cells was analyzed by western blotting with a rabbit anti-polyhistidine IgG. Tat-SOD (1 to 7 µM) or control SOD were added to the culture medium 
for 6 hours. The tissues were milled in liquid nitrogen after transduction and protein was extracted in 4 M guanidine hydrochloride buffer and dia-
lyzed. (b) Immunohistochemistry of cartilage explant transduced with Tat-SOD fusion protein (3 µM concentration of fusion protein added to the cul-
ture medium for 6 hours). The explants were fixed and sectioned in a cryotome after extensive washing. Cartilage sections were incubated with a 
mouse monoclonal anti-human Cu, Zn-SOD IgG and then visualized with a confocal scanning fluorescent microscope. Data are representative of 
seven samples from different donors. Scale bar = 100 µm.Available online http://arthritis-research.com/content/8/4/R96
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10% normal rabbit serum in PBS, immunohistochemistry was
performed using a mouse monoclonal anti-human Cu, Zn-
SOD IgG (dilution 1:500). The presence and distribution of
Cu, Zn-SOD were determined by a confocal scanning fluores-
cent microscope (LSM510, Zeiss).
Nitrate/nitrite quantification
The final products of NO in vivo are nitrite and nitrate, the sum
of which can be used as an index of total NO production.
Chondrocytes were transduced with Tat-SOD protein, control
SOD protein or Tat-GFP protein. After transduction, cells were
extensively washed, and fresh serum free DMEM with or with-
out IL-1 (1 ng/ml) was replenished. Culture media were har-
vested after 24 hours, and then analyzed using a nitrate/nitrite
colorimetric assay kit, as recommended by the manufacturer.
Briefly, nitrate was converted to nitrite using nitrate reductase,
and then the Griess reagents were added to form a deep-pur-
ple azo compound. Absorbance was measured at 540 nm
using a plate reader to determine nitrite concentrations. The
detection limit of the assay was 1 µM.
Reverse transcriptase-PCR
After transduction of monolayer chondrocytes, fresh serum
free DMEM with or without IL-1 (1 ng/ml) was replenished.
Total RNA was isolated from chondrocytes after 4 hours using
the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Total RNA
(200 ng) was reverse transcribed using the SuperScript™
First-strand synthesis system for reverse transcriptase (RT)-
PCR (Invitrogen, Gaithersburg, MD, USA) with oligo(dT)20
primers. PCR amplification of cDNA aliquots was performed
with the following sense and antisense primers (5'→3'): iNOS
sense, GTG AGG ATC AAA AAC TGG GG; iNOS antisense,
ACC TGC AGG TTG GAC CAC; glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) sense, CGA TGC TGG
GCG TGA GTA C; and GAPDH antisense, CGT TCA GCT
CAG GGA TGA CC. Reactions were processed through 25
cycles of 30 seconds of denaturation at 94°C, 1 minute of
annealing at 55°C for GAPDH and 30 cycles of 45 seconds
of denaturation at 95°C, 30 seconds of annealing at 55°C for
iNOS, followed by 1 minute of elongation at 72°C. PCR con-
ditions were chosen to be non-saturating in all cases. PCR
products were run on a 1.5% agarose gel, stained with ethid-
ium bromide and visualized using a UVP transilluminator(Ultra-
violet Product, Upland, CA). The band densities were
quantified using the National Institues of Health,(NIH) image
program (Bethesda, MD).
Data analysis
Data are expressed as means ± standard deviations. Differ-
ences between treatment groups were tested by using the
Mann-Whitney U test (GraphPad Prism, version 3, GraphPad
Software, San Diego, CA, USA). Significance was established
at the 95% confidence level (p < 0.05).
Results
Transduction of Tat-SOD into monolayer cultured 
chondrocytes
To determine whether Tat-SOD fusion protein is able to
traverse the membrane of cultured chondrocytes, we added a
variety of concentrations (1 to 7 µM) of fusion protein to the
culture media for 1 hour, and then determined the levels of pro-
tein transduced into the cells by western blotting. Neither Tat-
SOD nor control SOD fusion proteins were cytotoxic to
chondrocytes in the concentration range employed in our
experiment (data not shown). As shown in Figure 1a, Tat-SOD
was detected in chondrocyte lysates, whereas control SOD
was not. The transduction of Tat-SOD into cultured cells was
maximal at 3 µM and did not increase further by increasing the
concentration of the fusion protein. To determine the time-
dependence of Tat-SOD delivery into chondrocytes, 3 µM of
Tat-SOD protein was added to the culture media of monolayer
chondrocytes for 1 to 9 hours and the level of transduced pro-
teins was analyzed by western blotting. The transduction of
Tat-SOD into cultured chondrocytes was detected after 1
hour and the amount of transduced protein did not increase
further by increasing the duration of incubation (Figure 1b).
This result suggests that Tat-SOD was rapidly transduced into
the monolayer chondrocytes. The intracellular delivery of Tat-
SOD into cultured chondrocytes was further confirmed by
direct fluorescence analysis. Monolayer cultured chondro-
cytes were found to be transduced with Tat-SOD, whereas
only faint fluorescence signals similar to that of the back-
ground were detected in cells treated with control SOD (Fig-
ure 1c). The transduction efficiency was 91.6 ± 3.7% for Tat-
SOD concentration of 3 µM after 1 hour. The transduction effi-
ciency for Tat-GFP was similar to that for Tat-SOD (88.1 ±
9.1%; data not shown). The fluorescence signals detected in
the chondrocytes were largely in the cytoplasm, with a minority
of cells showing nuclear distribution. The restoration of
authentic properties of the transduced protein in cells is a key
issue in the application of protein transduction technology for
therapeutic use. Therefore, we determined the dismutase
activity of SOD in the chondrocytes treated with Tat-SOD and
compared it with those treated with control SOD; SOD
enzyme activity increased with the transduction of fusion pro-
tein into chondrocytes (Figure 1d). The intracellular dismutase
activity of SOD significantly increased after treatment with 1
µM Tat-SOD for 1 hour. These data demonstrate that Tat-
SOD fusion proteins were efficiently transduced into monol-
ayer cultured chondrocytes and the delivered protein main-
tained its properties.
Transduction of Tat-SOD into cartilage explant culture
Next, we tried to transduce the Tat-SOD proteins into
chondrocytes embedded in the extracellular matrix of carti-
lage. Human cartilage explants were treated with 1 to 7 µM of
fusion protein for 6 hours, and the levels of protein transduced
into the cells were analyzed by western blotting of protein
extracted from the explants. Faint but definite bands of trans-Arthritis Research & Therapy    Vol 8 No 4    Kim et al.
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duced protein probed by a rabbit anti-polyhistidine IgG were
detected in lysates from Tat-SOD transduced chondrocytes,
starting from a concentration of 3 µM (Figure 2a). Next, immu-
nohistochemistry was performed with a mouse monoclonal
anti-human Cu, Zn-SOD IgG in cartilage slices treated with 3
µM of Tat-SOD or control SOD; Cu, Zn-SOD was detected in
the explant culture with both treatments (Figure 2b). While the
intensity of staining tended to be stronger in Tat-SOD treated
explants, especially near the cut surface, there was no signifi-
cant difference in the percentage of positive chondrocytes
between Tat-SOD and control SOD treated explants (data not
shown), implying significant background expression of Cu, Zn-
SOD in human OA cartilage.
Figure 3
Regulation of nitric oxide and inducible nitric oxide synthase mRNA expression by transduced Tat-SOD Regulation of nitric oxide and inducible nitric oxide synthase mRNA expression by transduced Tat-SOD. (a) After monolayer cultured chondrocytes 
were transduced with 1 to 7 µM of Tat-SOD, control SOD or Tat-GFP proteins, serum free DMEM with or without IL-1 (1 ng/ml) was replenished. 
Culture media were harvested after 24 hours, and the production of nitric oxide(NO) was analyzed using a nitrate/nitrite colorimetric assay kit. The 
data are means and standard deviations of duplicate experiments from samples from three different donors. Asterisks denote p < 0.05 compared to 
control (IL-1 treatment alone). (b) Explant cultured chondrocytes were transduced with 1 to 7 µM of Tat-SOD, control SOD or Tat-GFP proteins, 
and serum free DMEM with or without IL-1 (1 ng/ml) was replenished. Culture media were harvested after 72 hours, and the production of NO was 
analyzed using a nitrate/nitrite colorimetric assay kit. The data are means and standard deviations of duplicate experiments from samples from three 
different donors. Asterisks denote p < 0.05 compared to control (IL-1 treatment alone). (c) Regulation of IL-1 stimulated NO production in chondro-
cytes by transduced Tat-GFP was observed in monolayer (left panel) and explant (right panel) cultured chondrocytes. Chondrocytes were trans-
duced with 1 to 7 µM of Tat-GFP, and serum free DMEM with or without IL-1 (1 ng/ml) was replenished. Culture media were harvested after 24 
hours for monolayer or 72 hours for explants, and the production of NO was analyzed using a nitrate/nitrite colorimetric assay kit. The data are means 
and standard deviations of duplicate experiments from samples from three different donors. (d) After transduction of chondrocytes with 3 µM of 
each fusion protein, serum free DMEM with or without IL-1 (1 ng/ml) was replenished. Total RNA was isolated from chondrocytes after 4 hours and 
RT-PCR was performed. Data are representative of four samples from different donors. The band densities for iNOS mRNA were quantified, the per-
cent GAPDH density was calculated for iNOS and the value for the control culture was set at 1. Asterisks denote p < 0.05.Available online http://arthritis-research.com/content/8/4/R96
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Effects of transduced Tat-SOD on IL-1 induced NO 
production and iNOS mRNA upregulation of 
chondrocytes
To determine whether the transduced fusion protein was func-
tionally active in the cells, we examined the effect of Tat-SOD
transduction on NO production induced by IL-1. As shown in
Figure 3a,b, both monolayer and explant chondrocytes pro-
duced significant NO after stimulation with 1 ng/ml IL-1. This
NO production was significantly down-regulated by pretreat-
ment with Tat-SOD fusion proteins, while control SOD failed
to reduce IL-1 induced NO production, indicating that trans-
duced Tat-SOD has a specific effect on down-regulation of
inflammatory signaling. Transduction with Tat-SOD also
resulted in significant down-regulation of iNOS mRNA tran-
scription observed after treatment of chondrocytes with IL-1
(Figure 3d). To demonstrate that internalization of the Tat
moiety itself has no effect on chondrocytes, Tat-GFP in addi-
tion to control SOD was used as a negative control. Tat-GFP
failed to reduce IL-1 induced NO production or iNOS mRNA
in chondrocytes (Figure 3c,d).
Discussion
In this study, the transduction of the full-length SOD protein
fused to HIV-1 Tat PTD into the cultured chondrocytes was
examined. Non-specific results were strictly excluded by inclu-
sion of a negative control SOD protein that carried six histidine
residues, the same as Tat-SOD, without an HIV-1 Tat PTD.
After extensive washing and stringent processing, the SOD
signal above background was detected in none of the control
SOD treated samples. In addition, Tat-GFP protein was
included to demonstrate that internalization of the Tat moiety
itself was not responsible for our results. Because chondro-
cytes are embedded in thick extracellular matrix, it is consid-
ered a challenge to deliver foreign genes or proteins into
chondrocytes in cartilage. However, our findings show delivery
of fusion proteins into the cartilage explant culture, demon-
strating that protein delivery employing Tat-PTD is a feasible
therapeutic approach for regulation of cartilage degeneration.
In our study, transduction of Tat-SOD into chondrocytes effec-
tively inhibited the production of the proinflammatory mediator
NO, which is induced by IL-1, both in monolayer and explant
cultures. However, Tat-SOD transduction failed to inhibit Met-
alloproteinase (MMP)-1, -3 and -13 expression or prostaglan-
din (PG) E2 activation induced by the same cytokine (data not
shown). A prior study of chondrocytes showed that treatment
of chondrocytes with IL-1 induces ROS, which includes both
hydrogen peroxide and superoxide, but that only superoxide
mediated IL-1 induced NF-kB activation and iNOS expression
[20]. The investigators did not report whether IL-1 induced
ROS or superoxide is responsible for stimulation of MMP in
chondrocytes. Based on our results, it is likely that MMP pro-
duction in chondrocytes in response to IL-1 is independent of
superoxide.
Several strategies are currently being developed to block the
proinflammatory pathway in arthritic diseases. Chemical com-
pounds are being developed, but it is very difficult to find a
compound that will specifically block a narrow target pathway.
Thus, they often lead to non-specific and widespread effects
that would make their clinical application difficult. Use of decoy
oligonucleotides and RNA interference technology to modu-
late the expression of proinflammatory genes are more specific
than chemical inhibitors. However, these therapies employing
gene delivery still pose more problems than solutions in terms
of efficiency, safety and inflammatory and immunogenic
effects elicited by viral vectors. Potential advantages in regu-
lating cellular functions using protein transduction technology
are: it allows for the application, in various pathological condi-
tions, of our accumulated knowledge on intracellular functions
of particular signaling pathways; the levels of protein inside
cells are directly and specifically regulated so that maximum
benefit can be achieved with minimal side effects; and it is
reversible and treatment can be terminated or can resume
after a resting period as deemed necessary [21]. Disadvan-
tages include the lack of target cell specificity, potential of
immunogenicity, and our incomplete knowledge of the molec-
ular mechanisms of protein transduction. Reports of the appli-
cation of PTD in potential therapeutic development are
increasing in various fields and in a variety of cell systems and
include inhibition of apoptosis by transduction of anti-apop-
totic Bcl-XL protein in explant cultured human chondrocytes
and in human islet cells [22,23], induction of chemosensitivity
by transduction of cytosine deaminase in human tumor cells
[24], and inhibition of proinflammatory signaling by transduc-
tion of superreppressor IkB in Jurkat T cells [21]. Protein trans-
duction therapy is also showing promise in in vivo models,
such as in the reduction of inflammation in carageenan-
induced pleurisy of Wistar rat and the reduction of pancreatic
islet cell toxicity in streptozotocin-induced diabetic mice
[25,26].
The mechanism by which Tat mediates cell entry has been a
focus of interest, and it has been shown that the entry medi-
ated by Tat-PTD is not dependent on a specific receptor,
energy generation or endocytosis [27]. Recent data provided
evidence that Tat-PTD binds to the negatively charged cell
surface constituents by electrostatic interaction and then stim-
ulates membrane ruffling to form heterogeneous vesicular
structures called macropinosomes [28]. It has also been
reported that Tat also promotes gene transfer into mammalian
cells, and may be a potential delivery vehicle for gene therapy
as well [29].
A recent report shows that extracellular SOD is decreased in
both human and animal models of OA, suggesting that inade-
quate control of reactive oxygen species plays a role in the
pathophysiology of OA [30].Arthritis Research & Therapy    Vol 8 No 4    Kim et al.
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Conclusion
This study demonstrates that protein delivery employing Tat-
PTD is feasible as a therapeutic modality to regulate catabolic
processes in cartilage. Construction of additional Tat-fusion
proteins that may stimulate anabolic activity or down-regulate
catabolic activity, and application to an in vivo model of arthri-
tis is the subject of future studies.
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